RESUMEN
Methods: Wound-healing assay and Transwell assay were utilized to evaluate the effect of ginsenoside Rb1 on the migration of BMSCs. RT-PCR and Western blotting were performed to evaluate the expression of stromal-derived factor 1 (SDF-1), C-X-C chemokine receptor type 4 (CXCR4), phosphatidylinositol 3-kinase (PI3K), and protein kinase B (PKB; AKT). Results: Ginsenoside Rb1 significantly enhanced the migration of BMSCs through the activation of SDF-1, CXCR4, p-PI3K/PI3K, and p-Akt/Akt relative expression. Furthermore, this stimulus was blocked by the pretreatment with AMD3100 and LY294002. Conclusions: Ginsenoside Rb1 facilitated the migration of BMSCs through the activation of the SDF-1/CXCR4 axis and PI3K/Akt pathway.
Asunto(s)
Ginsenósidos/metabolismo , Células Madre Mesenquimatosas/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Receptores CXCR4/metabolismo , Transducción de Señal , Animales , Huesos/metabolismo , Movimiento Celular/efectos de los fármacos , Cromonas/antagonistas & inhibidores , Ratones , Ratones Endogámicos C57BL , Morfolinas/antagonistas & inhibidores , Panax , Células del Estroma/metabolismoRESUMEN
BACKGROUND: Cancer progression following chemotherapy is a significant barrier to effective cancer treatment. We aimed to evaluate the role of drug-exposed cancer-associated fibroblasts (CAFs) in the growth and progression of drug-exposed gastric cancer (GC) cells and to explore the underlying molecular mechanism. METHODS: The human GC cell line 44As3 and CAFs were treated with 5-fluorouracil and oxaliplatin (5FU + OX). 5FU + OX-pretreated 44As3 cells were then cultured in a conditioned medium (CM) from 5FU + OX-pretreated CAFs, and the growth and migration/invasion ability of the cells were evaluated. We also compared the clinicopathological characteristics of the GC patients treated with S1 + OX in accordance with the properties of their resected specimens, focusing on the number of CAFs. Changes in gene expression in CAFs and 44As3 cells were comprehensively analyzed using RNA-seq analysis. RESULTS: The CM from 5FU + OX-pretreated CAFs promoted the migration and invasion of 5FU + OX-pretreated 44As3 cells. Although the number of cases was relatively small (n = 21), the frequency of positive cases of lymphovascular invasion and the recurrence rate were significantly higher in those with more residual CAF. RNA-seq analysis revealed 5FU + OX-pretreated CAF-derived glycoprotein 130 (gp130) as a candidate factor contributing to the increased migration of 5FU + OX-pretreated 44As3 cells. Administration of the gp130 inhibitor SC144 prevented the increased migration ability of 5FU + OX-pretreated 44As3 cells owing to drug-treated CAFs. CONCLUSIONS: Our findings provide evidence regarding the interactions between GC cells and CAFs in the tumor microenvironment following chemotherapy, suggesting that ligands for gp130 may be novel therapeutic targets for suppressing or preventing metastasis in GC.
Asunto(s)
Fibroblastos Asociados al Cáncer/efectos de los fármacos , Fluorouracilo/administración & dosificación , Oxaliplatino/administración & dosificación , Neoplasias Gástricas/tratamiento farmacológico , Microambiente Tumoral/efectos de los fármacos , Línea Celular Tumoral , Movimiento Celular/efectos de los fármacos , Expresión Génica/efectos de los fármacos , Humanos , Hidrazinas/administración & dosificación , Morfolinas/antagonistas & inhibidores , Quinoxalinas/administración & dosificación , Estómago/citología , Estómago/patologíaRESUMEN
Streptococcus pyogenes is a bacterium that causes systemic diseases such as pharyngitis and toxic shock syndrome. S. pyogenes produces molecules that inhibit the function of the human immune system, thus allowing growth and spread of the pathogen in tissues. It is known that S. pyogenes CAMP factor induces vacuolation in macrophages; however, the mechanism remains unclear. In the current study, the mechanism by which CAMP factor induces vacuolation in macrophages was investigated. CAMP factor was found to induce calcium ion uptake in murine macrophage RAW264.7 cells. In addition, EDTA inhibited calcium ion uptake and vacuolation in the cells. The L-type voltage-dependent calcium ion channel blockers nifedipine and verapamil reduced vacuolation. Furthermore, the phosphoinositide 3-kinase inhibitors LY294002 and wortmannin also inhibited the vacuolation induced by CAMP factor. Fluorescent microscopy revealed that clathrin localized to the vacuoles. These results suggest that the vacuolation is related to calcium ion uptake by RAW264.7 cells via L-type voltage-dependent calcium ion channels. Therefore, it was concluded that the vacuoles induced by S. pyogenes CAMP factor in macrophages are clathrin-dependent endosomes induced by activation of the phosphoinositide 3-kinase signaling pathway through calcium ion uptake.
Asunto(s)
Proteínas Bacterianas/metabolismo , Proteínas Bacterianas/farmacología , Calcio/metabolismo , Proteínas Hemolisinas/metabolismo , Proteínas Hemolisinas/farmacología , Streptococcus pyogenes/metabolismo , Animales , Cromonas/antagonistas & inhibidores , Ácido Edético/antagonistas & inhibidores , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Ratones , Morfolinas/antagonistas & inhibidores , Nifedipino/farmacología , Fosfatidilinositol 3-Quinasas/efectos de los fármacos , Células RAW 264.7/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Streptococcus pyogenes/inmunología , Vacuolas/efectos de los fármacos , Vacuolas/metabolismo , Verapamilo/farmacologíaRESUMEN
In recent years, cannabinoid typeâ 2 receptors (CB2 R) have emerged as promising therapeutic targets in a wide variety of diseases. Selective ligands of CB2 R are devoid of the psychoactive effects typically observed for CB1 R ligands. Based on our recent studies on a class of pyridazinone 4-carboxamides, further structural modifications of the pyridazinone core were made to better investigate the structure-activity relationships for this promising scaffold with the aim to develop potent CB2 R ligands. In binding assays, two of the new synthesized compounds [6-(3,4-dichlorophenyl)-2-(4-fluorobenzyl)-cis-N-(4-methylcyclohexyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide (2) and 6-(4-chloro-3-methylphenyl)-cis-N-(4-methylcyclohexyl)-3-oxo-2-pentyl-2,3-dihydropyridazine-4-carboxamide (22)] showed high CB2 R affinity, with Ki values of 2.1 and 1.6â nm, respectively. In addition, functional assays of these compounds and other new active related derivatives revealed their pharmacological profiles as CB2 R inverse agonists. Compound 22 displayed the highest CB2 R selectivity and potency, presenting a favorable inâ silico pharmacokinetic profile. Furthermore, a molecular modeling study revealed how 22 produces inverse agonism through blocking the movement of the toggle-switch residue, W6.48.
Asunto(s)
Antagonistas de Receptores de Cannabinoides/farmacología , Piridazinas/farmacología , Receptor Cannabinoide CB2/metabolismo , Animales , Benzoxazinas/antagonistas & inhibidores , Benzoxazinas/farmacología , Sitios de Unión , Células CHO , Antagonistas de Receptores de Cannabinoides/síntesis química , Antagonistas de Receptores de Cannabinoides/farmacocinética , Antagonistas de Receptores de Cannabinoides/toxicidad , Cricetulus , AMP Cíclico/metabolismo , Agonismo Inverso de Drogas , Humanos , Ligandos , Simulación del Acoplamiento Molecular , Estructura Molecular , Morfolinas/antagonistas & inhibidores , Morfolinas/farmacología , Naftalenos/antagonistas & inhibidores , Naftalenos/farmacología , Piridazinas/síntesis química , Piridazinas/farmacocinética , Piridazinas/toxicidad , Receptor Cannabinoide CB2/química , Relación Estructura-ActividadAsunto(s)
Anticoagulantes/efectos adversos , Bencimidazoles/efectos adversos , Morfolinas/efectos adversos , Pirazoles/efectos adversos , Piridonas/efectos adversos , Procedimientos Quirúrgicos Operativos , Tiofenos/efectos adversos , Heridas y Lesiones/cirugía , beta-Alanina/análogos & derivados , Anticoagulantes/antagonistas & inhibidores , Antídotos/uso terapéutico , Bencimidazoles/antagonistas & inhibidores , Dabigatrán , Urgencias Médicas , Humanos , Morfolinas/antagonistas & inhibidores , Pirazoles/antagonistas & inhibidores , Piridonas/antagonistas & inhibidores , Rivaroxabán , Procedimientos Quirúrgicos Operativos/métodos , Tiofenos/antagonistas & inhibidores , beta-Alanina/efectos adversos , beta-Alanina/antagonistas & inhibidoresRESUMEN
PURPOSE: Ceramide is glycosylated to glucosylceramide or lactosylceramide, and this glycosylation is a novel multidrug-resistance (MDR) mechanism. In this work, a short-chain ceramide (C6), lactosylceramide (LacCer), and an inhibitor of ceramide glycosylation (D-threo-1-phenyl-2-decanoylamino-3-1-propanol, PDMP) were evaluated on the proliferation of cervical cancer cells. The participation of glucosylceramide synthase (GCS), P-glycoprotein (P-gp), and multidrug-resistance gene-1 (MDR-1) in the resistance to the antiproliferative effect induced by C6 was also evaluated. METHODS: Cell proliferation was determined by crystal violet staining. GCS and MDR-1 mRNA expression was evaluated by real-time RT-PCR assay. GCS and P-gp protein expressions, as well as Rhodamine 123 uptake, which is a functional test for P-gp efflux activity, were determined by flow cytometry. RESULTS: C6 inhibited proliferation of CaLo and CasKi cells with an IC50 of 2.5 µM; however, 50% proliferation of ViBo cells was inhibited with 10 µM. LacCer increased the proliferation of all cells. When cells were treated with PDMP plus C6, no additional effect on antiproliferation induced by C6 was observed in CaLo and CasKi cells; however, proliferation diminished in comparison with C6 alone in ViBo cells. C6 increased GCS and MDR-1 expression in all cells, as well as P-gp expression in CasKi cells. CONCLUSIONS: Cells that have more capacity to glycosylate ceramide and express a higher level of GCS, MDR-1, and P-gp, are more resistant to the antiproliferative effect induced by C6.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Genes MDR/fisiología , Glucosiltransferasas/metabolismo , Lactosilceramidos/metabolismo , Morfolinas , Neoplasias del Cuello Uterino/metabolismo , Proliferación Celular/efectos de los fármacos , Resistencia a Antineoplásicos , Ensayos de Selección de Medicamentos Antitumorales , Femenino , Glicosilación/efectos de los fármacos , Humanos , Morfolinas/antagonistas & inhibidores , Morfolinas/metabolismo , Proteínas Asociadas a Resistencia a Múltiples Medicamentos , Células Tumorales CultivadasAsunto(s)
Anticoagulantes/efectos adversos , Hemorragia/inducido químicamente , Administración Oral , Anticoagulantes/administración & dosificación , Anticoagulantes/antagonistas & inhibidores , Anticoagulantes/farmacocinética , Antídotos/uso terapéutico , Bencimidazoles/administración & dosificación , Bencimidazoles/efectos adversos , Bencimidazoles/antagonistas & inhibidores , Bencimidazoles/farmacocinética , Vías Clínicas , Dabigatrán , Monitoreo de Drogas , Procedimientos Quirúrgicos Electivos , Hemorragia/terapia , Humanos , Morfolinas/administración & dosificación , Morfolinas/efectos adversos , Morfolinas/antagonistas & inhibidores , Morfolinas/farmacocinética , Pirazoles/administración & dosificación , Pirazoles/efectos adversos , Pirazoles/antagonistas & inhibidores , Pirazoles/farmacocinética , Piridinas/administración & dosificación , Piridinas/efectos adversos , Piridinas/antagonistas & inhibidores , Piridinas/farmacocinética , Piridonas/administración & dosificación , Piridonas/efectos adversos , Piridonas/antagonistas & inhibidores , Piridonas/farmacocinética , Factores de Riesgo , Rivaroxabán , Tiofenos/administración & dosificación , Tiofenos/efectos adversos , Tiofenos/antagonistas & inhibidores , Tiofenos/farmacocinéticaRESUMEN
Considering the existence of cross-tolerance between clonidine and morphine besides the same interaction between morphine and WIN 55,212-2 persuaded us to verify this fact between WIN 55,212-2 and clonidine in guinea pig ileum, which is a well-known model to examine the mode of action of cannabinoids and α2 -adenoceptor agonists The rectangular pulses were passed to the 0.5 g stretched ileum segments that were fixed in 20-ml organ bath. PowerLab system and Graphpad Prism were applied to record twitches and analyse the data. Electrically evoked contractions were dose-dependently inhibited by WIN 55,212-2 and clonidine (pD2 = 8.56 ± 0.41 and 7.65 ± 0.15, respectively). Tolerance to this effect could be induced by 4-h incubation with WIN 55,212-2 (3 × IC50 ) (pD2 = 6.36 ± 0.26, degree of tolerance: 159.32) (P < 0.01) but not with clonidine (2 × IC50 and 4 × IC50 ) for different time courses. Dose-response curve for inhibitory action of WIN 55,212-2 was shifted to the right after 4-h incubation with clonidine (3 × 10(-10) m) comparing to the untreated tissues (pD2 = 5.26 ± 0.69, degree of tolerance: 2000) (P < 0.001). This observation provides the evidence for the cannabinoid-noradrenergic systems interaction in the enteric nervous system as a simplified representative for central nervous system.
Asunto(s)
Benzoxazinas/antagonistas & inhibidores , Benzoxazinas/farmacología , Clonidina/farmacología , Tolerancia a Medicamentos , Sistema Nervioso Entérico/efectos de los fármacos , Íleon/efectos de los fármacos , Morfolinas/antagonistas & inhibidores , Morfolinas/farmacología , Naftalenos/antagonistas & inhibidores , Naftalenos/farmacología , Animales , Relación Dosis-Respuesta a Droga , Estimulación Eléctrica , Sistema Nervioso Entérico/fisiología , Cobayas , Íleon/fisiología , Técnicas In Vitro , Masculino , Contracción Muscular/efectos de los fármacos , Contracción Muscular/fisiologíaRESUMEN
INTRODUCTION: Anticoagulation therapies carry a risk of bleeding; reversal agents may be beneficial in cases of severe bleeding even for anticoagulants with a relatively short half-life, such as the oral factor Xa inhibitor rivaroxaban. MATERIALS AND METHODS: We investigated the in vitro reversal effect of prothrombin complex concentrate (PCC; 0.2-1.0U/mL), activated PCC (aPCC; 0.2-1.0U/mL) and recombinant activated factor VII (rFVIIa; 5-50µg/mL) on rivaroxaban-induced (200-1000ng/mL) changes in prothrombin time (PT) and thrombin generation (TG) in plasma, and in thromboelastometry (clotting time [CT]) in whole blood from healthy subjects. RESULTS: All three agents were partially effective in reversing rivaroxaban-induced anticoagulation but showed different profiles. rFVIIa and aPCC were more effective than PCC in reversing prolongations of PT, CT and TG lag time; rFVIIa was more effective than aPCC. However, the reversal effect reached a plateau with a maximal effect of approximately 50%. Inhibition of maximum thrombin concentration was slightly reversed by these agents; aPCC was the most effective. In contrast, inhibition of endogenous thrombin potential (ETP) was strongly reversed by aPCC, with significant increases over baseline at low rivaroxaban concentrations. Compared with aPCC, PCC showed a similar but less effective reversal profile. rFVIIa reversed ETP inhibition by approximately 50%. CONCLUSIONS: The extent of reversal by aPCC, PCC and rFVIIa was dependent on the parameter measured in rivaroxaban-anticoagulated plasma or blood. ETP measurements may have predictive power for assessing the reversal potential of PCC or aPCC and may be used to indicate an increased prothrombotic risk.
Asunto(s)
Anticoagulantes/administración & dosificación , Factores de Coagulación Sanguínea/farmacología , Pruebas de Coagulación Sanguínea/métodos , Coagulación Sanguínea/efectos de los fármacos , Factor VIIa/farmacología , Morfolinas/farmacología , Tiofenos/farmacología , Trombina/farmacología , Interacciones Farmacológicas , Factor VIIa/metabolismo , Humanos , Morfolinas/antagonistas & inhibidores , Proteínas Recombinantes/metabolismo , Proteínas Recombinantes/farmacología , Rivaroxabán , Tiofenos/antagonistas & inhibidores , TromboelastografíaAsunto(s)
Anticoagulantes/efectos adversos , Factores de Coagulación Sanguínea/uso terapéutico , Hematoma Subdural/tratamiento farmacológico , Hematoma Subdural/cirugía , Morfolinas/efectos adversos , Tiofenos/efectos adversos , Accidentes por Caídas , Anciano , Anticoagulantes/antagonistas & inhibidores , Coagulación Sanguínea/efectos de los fármacos , Coma/etiología , Coma/terapia , Femenino , Escala de Coma de Glasgow , Hematoma Subdural/inducido químicamente , Humanos , Morfolinas/antagonistas & inhibidores , Rivaroxabán , Tiofenos/antagonistas & inhibidores , Ultrasonografía Doppler TranscranealRESUMEN
PURPOSE OF REVIEW: Warfarin has been the sole oral anticoagulant used in the management of thromboembolic disorders for over 60 years. Target-specific oral anticoagulants (TSOAs) have recently emerged as alternatives to warfarin, because they do not require laboratory monitoring. Nevertheless, with the rising use of TSOAs, there is growing concern among clinicians regarding management of bleeding in patients taking them. Unlike warfarin, there is no antidote or reversal agent for TSOAs. This review summarizes recent developments and attempts to provide a systematic approach to patients on TSOAs presenting with bleeding complications. RECENT FINDINGS: Currently, data involving clinical management of TSOAs are limited and primarily based on ex-vivo or animal models using hemostatic agents with uncertain implications in bleeding patients. There is a pressing need for randomized clinical trials evaluating the safety and efficacy of hemostatic agents. SUMMARY: Without evidence-based guidelines for TSOA management, appropriate patient care requires an understanding of TSOA pharmacology, their effect on coagulation tests and, hence, a correct interpretation of test results, as well as a systematic approach to bleeding complications.
Asunto(s)
Antitrombinas/farmacología , Inhibidores del Factor Xa , Trastornos Hemorrágicos/tratamiento farmacológico , Anticoagulantes/antagonistas & inhibidores , Anticoagulantes/farmacocinética , Anticoagulantes/uso terapéutico , Antitrombinas/antagonistas & inhibidores , Bencimidazoles/antagonistas & inhibidores , Bencimidazoles/farmacología , Ensayos Clínicos como Asunto , Dabigatrán , Humanos , Morfolinas/antagonistas & inhibidores , Morfolinas/farmacología , Pirazoles/antagonistas & inhibidores , Pirazoles/farmacología , Piridonas/antagonistas & inhibidores , Piridonas/farmacología , Rivaroxabán , Tiofenos/antagonistas & inhibidores , Tiofenos/farmacología , beta-Alanina/análogos & derivados , beta-Alanina/antagonistas & inhibidores , beta-Alanina/farmacologíaRESUMEN
BACKGROUND: The involvement of glutamate system (particularly the NMDA and AMPA receptors) in the mechanism of antidepressant activity was demonstrated in preclinical and clinical studies. METHODS: In the present study, we investigated the effect of NMDA and AMPA receptors' ligands (agonists and antagonists) on the antidepressant-like activity of escitalopram, milnacipran, imipramine and reboxetine in the forced swim test in mice. RESULTS: Antidepressant activity (reduction in immobility time) of escitalopram and milnacipran but not of imipramine and reboxetine was antagonized by N-methyl-D-aspartate acid. CGP37849 (antagonist of the NMDA receptor) enhanced the antidepressant activity of all examined antidepressants. On the other hand, CX614 (a potentiator/positive allosteric modulator of the AMPA receptor) enhanced the antidepressant activity of imipramine and reboxetine but not of escitalopram and milnacipran in this test. NBQX (the AMPA receptor antagonist) did not influence the antidepressant activity of all tested agents. CONCLUSIONS: The data indicate the complex interactions following the activation or blockade of the NMDA and AMPA receptors with antidepressant drugs. The general phenomenon is the enhancing effect of the NMDA receptor antagonism on the antidepressant activity. Moreover, is can be concluded that the activity of antidepressants with a serotonergic mechanism of action can be inhibited by NMDA activation, while antidepressants with a noradrenergic mechanism of action are dependent on AMPA receptor transmission.
Asunto(s)
Antidepresivos/farmacología , Citalopram/farmacología , Ciclopropanos/farmacología , Pérdida de Tono Postural/efectos de los fármacos , Receptores AMPA/agonistas , Receptores AMPA/antagonistas & inhibidores , Receptores de N-Metil-D-Aspartato/agonistas , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , 2-Amino-5-fosfonovalerato/análogos & derivados , 2-Amino-5-fosfonovalerato/farmacología , Animales , Antidepresivos/agonistas , Antidepresivos/antagonistas & inhibidores , Citalopram/agonistas , Citalopram/antagonistas & inhibidores , Ciclopropanos/agonistas , Ciclopropanos/antagonistas & inhibidores , Imipramina/agonistas , Imipramina/antagonistas & inhibidores , Imipramina/farmacología , Masculino , Ratones , Milnaciprán , Morfolinas/agonistas , Morfolinas/antagonistas & inhibidores , Morfolinas/farmacología , Actividad Motora/efectos de los fármacos , N-Metilaspartato/farmacología , Oxazinas/farmacología , Quinoxalinas/farmacología , ReboxetinaRESUMEN
Warfarin has been the mainstay of oral anticoagulation for more than half a century. Within the last several years, 2 new classes of oral anticoagulants have been introduced as potential alternatives to warfarin for certain indications. The oral direct thrombin inhibitor, dabigatran, and 2 factor Xa inhibitors, rivaroxaban and apixaban, are the newest agents approved for use in the United States. These agents have been studied in various areas including stroke prophylaxis in atrial fibrillation, prevention and treatment of venous thromboembolism, and for reduction of ischemic events following acute coronary syndromes. While these agents do not require routine monitoring of international normalized ratio, these agents may be more challenging to reverse than traditional warfarin therapy. The following review will focus on describing the areas where the new oral anticoagulant agents have been studied, the basic pharmacologic characteristics of each agent, and how to appropriately manage the reversal of these agents when indicated.
Asunto(s)
Anticoagulantes/farmacología , Bencimidazoles/farmacología , Cuidados Críticos , Morfolinas/farmacología , Pirazoles/farmacología , Piridonas/farmacología , Tiofenos/farmacología , beta-Alanina/análogos & derivados , Administración Oral , Anticoagulantes/antagonistas & inhibidores , Bencimidazoles/antagonistas & inhibidores , Dabigatrán , Enoxaparina/antagonistas & inhibidores , Enoxaparina/farmacología , Humanos , Morfolinas/antagonistas & inhibidores , Pirazoles/antagonistas & inhibidores , Piridonas/antagonistas & inhibidores , Rivaroxabán , Tiofenos/antagonistas & inhibidores , Warfarina/antagonistas & inhibidores , Warfarina/farmacología , beta-Alanina/antagonistas & inhibidores , beta-Alanina/farmacologíaRESUMEN
PURPOSE: To describe the pharmacologic agents and strategies used for urgent reversal of warfarin and the target-specific oral anticoagulants dabigatran, rivaroxaban, and apixaban. SUMMARY: To reverse the anticoagulant effects of warfarin in patients who are bleeding or need surgery, exogenous vitamin K (phytonadione) may be used in combination with another, shorter-acting intervention, such as fresh frozen plasma (FFP), prothrombin complex concentrate (PCC), recombinant factor VIIa, or activated PCC (aPCC). Three-factor PCC contains factors II, IX, and X in an inactivated form, and four-factor PCC also includes factor VII in an inactivated form. No four-factor PCC products are available in the United States, but aPCC, which contains the same four factors with factor VII provided in an activated form, is available. The intervention depends on the International Normalized Ratio, presence of bleeding, and need for and timing of surgery. Research suggests that clotting factor concentrates are more effective than FFP alone for warfarin reversal. These products also may be useful for reversing the effects of target-specific oral anticoagulants, but limited efficacy and safety data are available to support their use. The risks and benefits associated with these products need to be weighed before their use for reversal of dabigatran, rivaroxaban, or apixaban. Additional clinical data are needed to clearly define the role of concentrated clotting factor products in reversal and to determine the optimal clotting factor concentrate product and dose for urgent reversal of oral anticoagulation. CONCLUSION: Phytonadione and clotting factor concentrates appear to have a role for reversal of warfarin, and limited evidence suggests that clotting factor concentrates could have a role in reversal of target-specific oral anticoagulants in an emergency situation.
Asunto(s)
Anticoagulantes/efectos adversos , Anticoagulantes/antagonistas & inhibidores , Antifibrinolíticos/administración & dosificación , Factores de Coagulación Sanguínea/administración & dosificación , Pérdida de Sangre Quirúrgica/prevención & control , Hemorragia/prevención & control , Plasma , Vitamina K 1/administración & dosificación , Administración Oral , Anticoagulantes/administración & dosificación , Antitrombinas/efectos adversos , Antitrombinas/antagonistas & inhibidores , Bencimidazoles/efectos adversos , Bencimidazoles/antagonistas & inhibidores , Dabigatrán , Quimioterapia Combinada , Urgencias Médicas , Hemorragia/inducido químicamente , Humanos , Relación Normalizada Internacional , Morfolinas/efectos adversos , Morfolinas/antagonistas & inhibidores , Pirazoles/efectos adversos , Pirazoles/antagonistas & inhibidores , Piridonas/efectos adversos , Piridonas/antagonistas & inhibidores , Rivaroxabán , Procedimientos Quirúrgicos Operativos/efectos adversos , Tiofenos/efectos adversos , Tiofenos/antagonistas & inhibidores , Tromboembolia/etiología , Tromboembolia/prevención & control , Resultado del Tratamiento , Warfarina/efectos adversos , Warfarina/antagonistas & inhibidores , beta-Alanina/efectos adversos , beta-Alanina/análogos & derivados , beta-Alanina/antagonistas & inhibidoresRESUMEN
BACKGROUND: Rivaroxaban has been approved as an antithrombotic agent for prevention of venous thromboembolism with specific indications. At present no antidote is appointed and no guidelines have been formulated for the measurement of Rivaroxaban reversal. OBJECTIVES: In the present study, we have evaluated the influence of prothrombin complex concentrate (PCC) on the anticoagulant effects of Rivaroxaban as measured by prothrombin time (PT) and thrombin generation tests (TGTs). METHODS: Plasma and whole blood samples from healthy volunteers were spiked with Rivaroxaban (up to 800 µg L(-1) ) and PCC was added to these samples in concentration ranges as used clinically to reverse the effects of vitamin K antagonists. PT, endogenous thrombin potential (ETP) and calibrated automated thrombography (CAT) assays were performed with varying tissue factor (TF) concentrations. RESULTS: Addition of PCC to Rivaroxaban-spiked samples did not result in normalization of PT and TGT lag time/T-Lag in ETP and CAT, respectively. In contrast, normalization of ETP and CAT area under the curve did occur. However, the response to PCC addition was strongly TF concentration dependent and in whole blood less PCC was required for Rivaroxaban reversal as compared with plasma. CONCLUSIONS: Prothrombin complex concentrate does not neutralize the lengthening effect on PT and TGT lag time/T-Lag of Rivaroxaban anticoagulated blood in vitro; however, total thrombin potential could be normalized. Response of the different TGTs in this respect is assay condition dependent. Therefore, prospective studies are needed to clarify which assay condition and parameter describes in vivo hemostasis best in patients on Rivaroxaban who are treated with PCC.
Asunto(s)
Anticoagulantes/antagonistas & inhibidores , Factores de Coagulación Sanguínea/uso terapéutico , Morfolinas/antagonistas & inhibidores , Morfolinas/química , Tiofenos/antagonistas & inhibidores , Tiofenos/química , Trombina/química , Anticoagulantes/química , Área Bajo la Curva , Coagulación Sanguínea/efectos de los fármacos , Pruebas de Coagulación Sanguínea , Calibración , Fibrinolíticos/química , Humanos , Plasma/efectos de los fármacos , Protrombina/química , Tiempo de Protrombina , Rivaroxabán , Tromboplastina/química , Factores de Tiempo , Vitamina K/antagonistas & inhibidoresRESUMEN
Omentin is a recently identified adipocytokine, and we previously demonstrated that omentin played anti-inflammatory roles in vascular endothelial and smooth muscle cells. We also demonstrated that omentin induced vasodilation in rat isolated blood vessels. However, effects of omentin on blood pressure (BP) are not determined. Here, we examined whether intravenously injected omentin acutely alters BP of Wistar rats. Omentin (0.06-18 µg/kg) alone did not alter BP of Wistar rats. On the other hand, omentin (18 µg/kg) significantly inhibited noradrenaline (NA; 2 µg/kg)-induced increases in systolic BP and mean BP. Omentin (18 µg/kg) significantly inhibited angiotensin II (1 µg/kg)-induced increases in diastolic BP. Omentin (18 µg/kg) significantly inhibited dimorpholamine (3 mg/kg)-induced increases in diastolic BP. Omentin (18 µg/kg) failed to inhibit the NA (0.02-2 µg/kg)-induced increases of systolic BP in the nitric oxide (NO) synthase inhibitor, N(G)-nitro-l-arginine methyl ester (80 mg/kg, 1 day)-treated Wistar rats. In summary, we for the first time demonstrated that omentin inhibited agonists-induced increases in BP. The effect of omentin was suggested to be mediated likely via NO-dependent mechanism.
Asunto(s)
Angiotensinas/antagonistas & inhibidores , Presión Sanguínea/efectos de los fármacos , Citocinas/farmacología , Lectinas/farmacología , Norepinefrina/antagonistas & inhibidores , Análisis de Varianza , Animales , Citocinas/administración & dosificación , Proteínas Ligadas a GPI/administración & dosificación , Proteínas Ligadas a GPI/farmacología , Inyecciones Intravenosas , Lectinas/administración & dosificación , Morfolinas/antagonistas & inhibidores , Ácido Nítrico/metabolismo , Ratas , Ratas WistarRESUMEN
Mosapride citrate hydrate (mosapride) has been known to act as a 5-HT4 agonist and to enhance gastric emptying. However, its mode of action, such as time course and dosage effect, on gastric emptying has not been clarified. This study aimed to clarify these points by the breath test using [1-(13)C]acetic acid in conscious rats. Mosapride significantly and dose-dependently enhanced the gastric emptying increased Cmax and AUC120 min at doses between 0.1 and 3 mg/kg. Pre-treatment with GR113808 (5-HT4 antagonist) significantly attenuated the enhancement of gastric emptying by mosapride. On the contrary, at a dose of 30 mg/kg, mosapride significantly inhibited the gastric emptying. The major metabolite (M1: 5-HT3 receptor antagonist) significantly inhibited gastric emptying at doses of 19.2 and 64.1 mg/kg (equimolar to 30 and 100 mg/kg of mosapride, respectively), suggesting that the inhibitory effect by mosapride may be caused at least in part by the 5-HT3 receptor antagonistic effect of M1. These findings show that mosapride has dual role on the gastric emptying and may support the usefulness of mosapride for the therapy of postprandial distress syndrome such as early satiation and postprandial fullness.
Asunto(s)
Benzamidas/farmacología , Pruebas Respiratorias/métodos , Vaciamiento Gástrico/efectos de los fármacos , Morfolinas/farmacología , Antagonistas del Receptor de Serotonina 5-HT3 , Agonistas del Receptor de Serotonina 5-HT4 , Ácido Acético , Animales , Benzamidas/antagonistas & inhibidores , Benzamidas/metabolismo , Radioisótopos de Carbono , Depresión Química , Relación Dosis-Respuesta a Droga , Indoles/farmacología , Masculino , Morfolinas/antagonistas & inhibidores , Morfolinas/metabolismo , Radiofármacos , Ratas , Ratas Sprague-Dawley , Receptor Muscarínico M1 , Antagonistas del Receptor de Serotonina 5-HT4/farmacología , Estimulación Química , Sulfonamidas/farmacologíaRESUMEN
Inhibitors of coagulation factor Xa (fXa) have emerged as a new class of antithrombotics but lack effective antidotes for patients experiencing serious bleeding. We designed and expressed a modified form of fXa as an antidote for fXa inhibitors. This recombinant protein (r-Antidote, PRT064445) is catalytically inactive and lacks the membrane-binding γ-carboxyglutamic acid domain of native fXa but retains the ability of native fXa to bind direct fXa inhibitors as well as low molecular weight heparin-activated antithrombin III (ATIII). r-Antidote dose-dependently reversed the inhibition of fXa by direct fXa inhibitors and corrected the prolongation of ex vivo clotting times by such inhibitors. In rabbits treated with the direct fXa inhibitor rivaroxaban, r-Antidote restored hemostasis in a liver laceration model. The effect of r-Antidote was mediated by reducing plasma anti-fXa activity and the non-protein bound fraction of the fXa inhibitor in plasma. In rats, r-Antidote administration dose-dependently and completely corrected increases in blood loss resulting from ATIII-dependent anticoagulation by enoxaparin or fondaparinux. r-Antidote has the potential to be used as a universal antidote for a broad range of fXa inhibitors.
Asunto(s)
Anticoagulantes/antagonistas & inhibidores , Antídotos/farmacología , Inhibidores del Factor Xa , Proteínas Recombinantes/farmacología , Animales , Benzamidas/antagonistas & inhibidores , Relación Dosis-Respuesta a Droga , Enoxaparina/antagonistas & inhibidores , Factor Xa/farmacología , Fondaparinux , Hemorragia/tratamiento farmacológico , Hemostasis/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos C57BL , Morfolinas/antagonistas & inhibidores , Polisacáridos/antagonistas & inhibidores , Pirazoles/antagonistas & inhibidores , Piridinas/antagonistas & inhibidores , Piridonas/antagonistas & inhibidores , Conejos , Ratas , Ratas Sprague-Dawley , Rivaroxabán , Tiofenos/antagonistas & inhibidoresRESUMEN
Although it is well established that cannabinoid drugs can influence cognitive performance, the findings-describing both enhancing and impairing effects-have been ambiguous. Here, we investigated the effects of posttraining systemic administration of the synthetic cannabinoid agonist WIN55,212-2 (0.1, 0.3, or 1.0 mg/kg) on short- and long-term retention of object recognition memory under two conditions that differed in their training-associated arousal level. In male Sprague-Dawley rats that were not previously habituated to the experimental context, WIN55,212-2 administered immediately after a 3-min training trial, biphasically impaired retention performance at a 1-h interval. In contrast, WIN55,212-2 enhanced 1-h retention of rats that had received extensive prior habituation to the experimental context. Interestingly, immediate posttraining administration of WIN55,212-2 to non-habituated rats, in doses that impaired 1-h retention, enhanced object recognition performance at a 24-h interval. Posttraining WIN55,212-2 administration to habituated rats did not significantly affect 24-h retention. In light of intimate interactions between cannabinoids and the hypothalamic-pituitary-adrenal axis, we further investigated whether cannabinoid administration might differently influence training-induced glucocorticoid activity in rats in these two habituation conditions. WIN55,212-2 administered after object recognition training elevated plasma corticosterone levels in non-habituated rats whereas it decreased corticosterone levels in habituated rats. Most importantly, following pretreatment with the corticosterone-synthesis inhibitor metyrapone, WIN55,212-2 effects on 1- and 24-h retention of non-habituated rats became similar to those seen in the low-aroused habituated animals, indicating that cannabinoid-induced regulation of adrenocortical activity contributes to the environmentally sensitive effects of systemically administered cannabinoids on short- and long-term retention of object recognition memory.
Asunto(s)
Nivel de Alerta , Benzoxazinas/farmacología , Corticosterona/sangre , Emociones , Conducta Exploratoria/efectos de los fármacos , Habituación Psicofisiológica/efectos de los fármacos , Morfolinas/farmacología , Naftalenos/farmacología , Reconocimiento en Psicología/efectos de los fármacos , Animales , Benzoxazinas/antagonistas & inhibidores , Agonistas de Receptores de Cannabinoides/farmacología , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/farmacología , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Masculino , Metirapona/farmacología , Morfolinas/antagonistas & inhibidores , Naftalenos/antagonistas & inhibidores , Sistema Hipófiso-Suprarrenal/efectos de los fármacos , Ratas , Retención en Psicología/efectos de los fármacos , Factores de TiempoRESUMEN
In vivo effects of cannabinoid (CB) agonists are often assessed using four well-established measures: locomotor activity, hypothermia, cataleptic-like effects, and analgesia. The present studies demonstrate that doses of CB agonists that produce these effects also reliably increase diuresis. Diuretic effects of several CB agonists were measured in female rats over 2 hours immediately after drug injection, and results were compared with hypothermic effects. Direct-acting CB1 agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9ß-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9ß-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia. The highest doses of cannabinoid drugs yielded, on average, 26-32 g/kg urine; comparable effects were obtained with 10 mg/kg furosemide and 3.0 mg/kg trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide (U50-488). Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the CB2 agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects. In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]. These data indicate that cannabinoids have robust diuretic effects in rats that are mediated via CB1 receptor mechanisms.